Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?

[...]450 exonic variants in DPYD with potentially damaging effect have been reported (7). [...]to 5-FU, capecitabine and its downstream metabolites are observed only at low concentrations in plasma due to its intracellular activation, making TDM more challenging (15). [...]pharmacogenetic testing ma...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2018-06, Vol.19 (8), p.689-692
Main Authors: Hamzic, Seid, Amstutz, Ursula, Largiadèr, Carlo R
Format: Article
Language:English
Subjects:
5-FU
Binding sites
Body composition
BSA-based dosing
Cancer therapies
capecitabine
Chemotherapy
Clinical trials
Colorectal cancer
Dehydrogenases
DPYD
Drug dosages
Enzymes
Gender differences
Genotyping
Metabolism
Metabolites
MicroRNAs
Mutation
pharmacogenetics
TDM
Toxicity
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3
cites cdi_FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3
container_end_page 692
container_issue 8
container_start_page 689
container_title Pharmacogenomics
container_volume 19
creator Hamzic, Seid
Amstutz, Ursula
Largiadèr, Carlo R
description [...]450 exonic variants in DPYD with potentially damaging effect have been reported (7). [...]to 5-FU, capecitabine and its downstream metabolites are observed only at low concentrations in plasma due to its intracellular activation, making TDM more challenging (15). [...]pharmacogenetic testing may be even more relevant in Cp-treated patients, where routine TDM currently is not feasible. [...]more research is needed to replicate these associations and better understand the impact of these genes and variants on Cp-related toxicities. Besides genotyping, there have been reports on various phenotypic approaches to detect reduced DPD activity pretherapy. [...]no matter which pretherapeutic tests will eventually find their way into routine care, TDM should always complement these methods, at least for the initial cycles, for optimal FP dose individualization.
doi_str_mv 10.2217/pgs-2018-0040
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2326937813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2326937813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3</originalsourceid><addsrcrecordid>eNp1kE2P1SAUholx4nzo0q0hcWsdvlrAjZncODrJJG50TSgcbpi0pUKr038v9Y7uXMFLnvOS8yD0mpL3jFF5PR9LwwhVDSGCPEMXVArRKCLY83oXHWuYoN05uizlgRBGO0FeoHOmpeJKygu0HNII2OIhTUf8y27vcFniMNSXGgpeEj6mDzjkNOI5g49uiRW0k9_jT5j-xDCsKad5y3GMPk5Qxx6ji8u2z8fJZbAFPIYQorNu-_gSnQU7FHj1dF6h77efvh2-NPdfP98dbu4bJyhZGqDcadf1Uraa2ACdslwzwVnvvehaoq2HQLysiyjegdKh1Vq1fa9bpnpv-RV6e-qdc_qxQlnMQ1rzVL80jLNOc6kor1RzolxOpWQIZq6L2LwZSszu2FTHZndsdseVf_PUuvYj-H_0X6kV0CcgrMuaobgIkwNzSuMusTr6T_lvrz2MIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326937813</pqid></control><display><type>article</type><title>Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?</title><source>PubMed (Medline)</source><creator>Hamzic, Seid ; Amstutz, Ursula ; Largiadèr, Carlo R</creator><creatorcontrib>Hamzic, Seid ; Amstutz, Ursula ; Largiadèr, Carlo R</creatorcontrib><description>[...]450 exonic variants in DPYD with potentially damaging effect have been reported (7). [...]to 5-FU, capecitabine and its downstream metabolites are observed only at low concentrations in plasma due to its intracellular activation, making TDM more challenging (15). [...]pharmacogenetic testing may be even more relevant in Cp-treated patients, where routine TDM currently is not feasible. [...]more research is needed to replicate these associations and better understand the impact of these genes and variants on Cp-related toxicities. Besides genotyping, there have been reports on various phenotypic approaches to detect reduced DPD activity pretherapy. [...]no matter which pretherapeutic tests will eventually find their way into routine care, TDM should always complement these methods, at least for the initial cycles, for optimal FP dose individualization.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2018-0040</identifier><identifier>PMID: 29783877</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>5-FU ; Binding sites ; Body composition ; BSA-based dosing ; Cancer therapies ; capecitabine ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Dehydrogenases ; DPYD ; Drug dosages ; Enzymes ; Gender differences ; Genotyping ; Metabolism ; Metabolites ; MicroRNAs ; Mutation ; pharmacogenetics ; TDM ; Toxicity ; Women</subject><ispartof>Pharmacogenomics, 2018-06, Vol.19 (8), p.689-692</ispartof><rights>2018 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jun 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3</citedby><cites>FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29783877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamzic, Seid</creatorcontrib><creatorcontrib>Amstutz, Ursula</creatorcontrib><creatorcontrib>Largiadèr, Carlo R</creatorcontrib><title>Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>[...]450 exonic variants in DPYD with potentially damaging effect have been reported (7). [...]to 5-FU, capecitabine and its downstream metabolites are observed only at low concentrations in plasma due to its intracellular activation, making TDM more challenging (15). [...]pharmacogenetic testing may be even more relevant in Cp-treated patients, where routine TDM currently is not feasible. [...]more research is needed to replicate these associations and better understand the impact of these genes and variants on Cp-related toxicities. Besides genotyping, there have been reports on various phenotypic approaches to detect reduced DPD activity pretherapy. [...]no matter which pretherapeutic tests will eventually find their way into routine care, TDM should always complement these methods, at least for the initial cycles, for optimal FP dose individualization.</description><subject>5-FU</subject><subject>Binding sites</subject><subject>Body composition</subject><subject>BSA-based dosing</subject><subject>Cancer therapies</subject><subject>capecitabine</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Dehydrogenases</subject><subject>DPYD</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Gender differences</subject><subject>Genotyping</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>MicroRNAs</subject><subject>Mutation</subject><subject>pharmacogenetics</subject><subject>TDM</subject><subject>Toxicity</subject><subject>Women</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kE2P1SAUholx4nzo0q0hcWsdvlrAjZncODrJJG50TSgcbpi0pUKr038v9Y7uXMFLnvOS8yD0mpL3jFF5PR9LwwhVDSGCPEMXVArRKCLY83oXHWuYoN05uizlgRBGO0FeoHOmpeJKygu0HNII2OIhTUf8y27vcFniMNSXGgpeEj6mDzjkNOI5g49uiRW0k9_jT5j-xDCsKad5y3GMPk5Qxx6ji8u2z8fJZbAFPIYQorNu-_gSnQU7FHj1dF6h77efvh2-NPdfP98dbu4bJyhZGqDcadf1Uraa2ACdslwzwVnvvehaoq2HQLysiyjegdKh1Vq1fa9bpnpv-RV6e-qdc_qxQlnMQ1rzVL80jLNOc6kor1RzolxOpWQIZq6L2LwZSszu2FTHZndsdseVf_PUuvYj-H_0X6kV0CcgrMuaobgIkwNzSuMusTr6T_lvrz2MIQ</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Hamzic, Seid</creator><creator>Amstutz, Ursula</creator><creator>Largiadèr, Carlo R</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20180601</creationdate><title>Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?</title><author>Hamzic, Seid ; Amstutz, Ursula ; Largiadèr, Carlo R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>5-FU</topic><topic>Binding sites</topic><topic>Body composition</topic><topic>BSA-based dosing</topic><topic>Cancer therapies</topic><topic>capecitabine</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Dehydrogenases</topic><topic>DPYD</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Gender differences</topic><topic>Genotyping</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>MicroRNAs</topic><topic>Mutation</topic><topic>pharmacogenetics</topic><topic>TDM</topic><topic>Toxicity</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamzic, Seid</creatorcontrib><creatorcontrib>Amstutz, Ursula</creatorcontrib><creatorcontrib>Largiadèr, Carlo R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (ProQuest Medical &amp; Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK &amp; Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamzic, Seid</au><au>Amstutz, Ursula</au><au>Largiadèr, Carlo R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>19</volume><issue>8</issue><spage>689</spage><epage>692</epage><pages>689-692</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>[...]450 exonic variants in DPYD with potentially damaging effect have been reported (7). [...]to 5-FU, capecitabine and its downstream metabolites are observed only at low concentrations in plasma due to its intracellular activation, making TDM more challenging (15). [...]pharmacogenetic testing may be even more relevant in Cp-treated patients, where routine TDM currently is not feasible. [...]more research is needed to replicate these associations and better understand the impact of these genes and variants on Cp-related toxicities. Besides genotyping, there have been reports on various phenotypic approaches to detect reduced DPD activity pretherapy. [...]no matter which pretherapeutic tests will eventually find their way into routine care, TDM should always complement these methods, at least for the initial cycles, for optimal FP dose individualization.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29783877</pmid><doi>10.2217/pgs-2018-0040</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-2416
ispartof Pharmacogenomics, 2018-06, Vol.19 (8), p.689-692
issn 1462-2416
1744-8042
language eng
recordid cdi_proquest_journals_2326937813
source PubMed (Medline)
subjects 5-FU
Binding sites
Body composition
BSA-based dosing
Cancer therapies
capecitabine
Chemotherapy
Clinical trials
Colorectal cancer
Dehydrogenases
DPYD
Drug dosages
Enzymes
Gender differences
Genotyping
Metabolism
Metabolites
MicroRNAs
Mutation
pharmacogenetics
TDM
Toxicity
Women
title Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A12%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Come%20a%20long%20way,%20still%20a%20ways%20to%20go:%20from%20predicting%20and%20preventing%20fluoropyrimidine%20toxicity%20to%20increased%20efficacy?&rft.jtitle=Pharmacogenomics&rft.au=Hamzic,%20Seid&rft.date=2018-06-01&rft.volume=19&rft.issue=8&rft.spage=689&rft.epage=692&rft.pages=689-692&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2018-0040&rft_dat=%3Cproquest_cross%3E2326937813%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c410t-e13c9c6b77590afe68a392432bdd46509adef0d7877836e89f59985bb9528bda3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2326937813&rft_id=info:pmid/29783877&rfr_iscdi=true